Genesys Biolabs introduces New Blood Test for Early Detection of Lung Cancer
Genesys Biolabs, of Rockville Maryland, has introduced a new blood test to assist in the early detection of lung cancer. Suggested candidates for this test are persons at high risk, which includes heavy smokers and former smokers over age 50, who have no symptoms of lung cancer and who are not currently getting yearly CT scans for lung cancer.
The test is ordered from the patient’s doctor’s office where a blood sample is drawn. The sample is sent to Genesys’s CLIA certified laboratory, located in Rockville, MD, where our proprietary biomarker test will be performed measuring 6 different protein analytes in the blood sample.
We have named this test “PAULA’s” test which is both an acronym for “Protein Assays Using Lung cancer Analytes” and is named in memory of Paula Shore, the wife of a shareholder who succumbed to lung cancer in 2005.
A few days after receiving the blood sample, Genesys Biolabs will forward the physician a report with a PAULA’s Test score. This score will help determine the likelihood that the patient has lung cancer relative to others with similar smoking histories. Patients are then directed to the appropriate diagnostic follow up.
Ideally, high risk patients should receive a PAULA’s test yearly for the best chances of detecting lung cancer at its earliest stage. With regular testing using our test, physicians can triage high-risk patients to CT before symptoms present. When used in conjunction with PAULA’s Test, these imaging tests should generate substantially fewer false positives.